Patent_application_number,Applicant_name,Year_of_application,Patent_system
EP2275560A2,BASF,2011,EPO
EP2277913A2,UNIVERSITY OF ABERDEEN,2011,EPO
EP2277914A2,UNIVERSITY OF ABERDEEN,2011,EPO
EP2278015A1,DU PONT,2011,EPO
EP2281837A2,UNIVERSITY OF ABERDEEN,2011,EPO
EP2285964A1,UNIVERSITY OF SASKATCHEWAN,2011,EPO
EP2287300A1,IDEMITSU KOSAN,2011,EPO
EP2287317A2,DU PONT,2011,EPO
EP2290085A2,DU PONT,2011,EPO
EP2291553A1,"VERACYTE, INC",2011,EPO
EP2292766A2,TAKARA HOLDINGS,2011,EPO
EP2292767A2,TAKARA HOLDINGS,2011,EPO
EP2294193A2,DSM IP ASSETS BV,2011,EPO
EP2294198A1,FONTERRA,2011,EPO
EP2305717A1,KONINK NL AKADEMIE VAN WETENSCHAPPEN [NL],2011,EPO
EP2314682A2,RIKEN,2011,EPO
EP2314684A1,JSR CORPORATION,2011,EPO
EP2321412A2,BAYER,2011,EPO
EP2322535A2,YALE UNIVERSITY,2011,EPO
EP2325300A1,ABBOTT LABORATORIES,2011,EPO
EP2325304A1,ILLUMINA CAMBRIDGE LTD [GB],2011,EPO
EP2325322A1,AGENUS,2011,EPO
EP2329846A1,UNIV MARYLAND BIOTECH INST [US],2011,EPO
EP2333052A1,ABBOTT LABORATORIES,2011,EPO
EP2333054A2,KIOST,2011,EPO
EP2333071A1,DSM IP ASSETS BV,2011,EPO
EP2333072A1,DSM IP ASSETS BV,2011,EPO
EP2333073A1,DSM IP ASSETS BV,2011,EPO
EP2336155A1,CNRS,2011,EPO
EP2338985A1,INST UNIV DE CIENCIA,2011,EPO
EP2346992A1,MA KESEN [CA]; YING XIANGXIAN [CN],2011,EPO
EP2350132A2,INTERNAT VACCINE INST [KR],2011,EPO
EP2352818A2,ROCHE,2011,EPO
EP2352824A2,CHEVRON,2011,EPO
EP2357243A2,CSIRO,2011,EPO
EP2357244A2,CSIRO,2011,EPO
EP2358882A1,CSIRO,2011,EPO
EP2363492A2,CSIRO,2011,EPO
EP2365097A1,ENTERPRISE IRELAND (BIORESEARCH IRELAND),2011,EPO
EP2366781A1,BASF,2011,EPO
EP2366804A1,GOVERNMENT OF FRANCE,2011,EPO
EP2367947A2,CHEVRON,2011,EPO
EP2371953A1,RIKEN,2011,EPO
EP2374891A2,PRECIGEN,2011,EPO
EP2380982A1,SCRIPPS RESEARCH INSTITUTE,2011,EPO
EP2380984A2,BASF,2011,EPO
EP2381761A1,SAPPHIRE ENERGY INC [US],2011,EPO
EP2383291A2,RSR LIMITED,2011,EPO
EP2383340A2,SCRIPPS RESEARCH INSTITUTE,2011,EPO
EP2386570A1,TARGET HEART BIOTEC S R L [IT],2011,EPO
EP2388332A1,BASF,2011,EPO
EP2392664A2,DU PONT,2011,EPO
EP2395074A1,CHEVRON,2011,EPO
EP2395091A2,BASF,2011,EPO
EP2395092A2,BASF,2011,EPO
EP2395093A2,BASF,2011,EPO
EP2397552A1,NATIONAL RESEARCH COUNCIL CANADA,2011,EPO
JP2011013231A,BAXTER INTERNATIONAL,2011,JPO
JP2011024501A,TORAY,2011,JPO
JP2011024503A,TOYOTA,2011,JPO
JP2011024579A,"A GREY CRAIG,DAVID GRIFFEN,BALDOMERO M OLIVERA,MAREN WATKINS, DAVID R HILLYARD,JULITA IMPERIAL,LOURDES J CRUZ,JOHN D WAGSTAFF, RICHARD T LAYER,ROBERT M JONES,R TYLER MCCABE,COGNETIX INC, UNIVERSITY OF UTAH",2011,JPO
JP2011036252A,STEPHEN R HAMILTON,2011,JPO
JP2011036262A,RIKEN,2011,JPO
JP2011055731A,OSAKA UNIVERSITY,2011,JPO
JP2011062202A,ENTERPRISE IRELAND (BIORESEARCH IRELAND),2011,JPO
JP2011067105A,MITSUBISHI,2011,JPO
JP2011083251A,KAGAWA UNIVERSITY,2011,JPO
JP2011083275A,HOKKAIDO UNIVERSITY,2011,JPO
JP2011087578A,BASF,2011,JPO
JP2011087583A,BASF,2011,JPO
JP2011092198A,THE UNIVERSITY OF CHICAGO,2011,JPO
JP2011097922A,CENTRAL RESEARCH INSTITUTE OF ELECTRIC POWER INDUSTRY,2011,JPO
JP2011125267A,NIPRO CORP,2011,JPO
JP2011155988A,ANZA THERAPEUTICS INC,2011,JPO
JP2011167133A,"GEKKEIKAN SAKE COMPANY LTD,KOBE UNIVERSITY",2011,JPO
JP2011167191A,DU PONT,2011,JPO
JP2011172566A,BASF,2011,JPO
JP2011182796A,ODYSSEY THERAPEUTICS,2011,JPO
JP2011190210A,SUMITOMO CHEMICAL,2011,JPO
JP2011195491A,UNIVERSITY OF TSUKUBA,2011,JPO
JP2011200145A,TOKYO UNIVERSITY,2011,JPO
JP2011200153A,TOYOTA,2011,JPO
JP2011219392A,CHISSO CORPORATION,2011,JPO
JP2011223885A,JAPAN TOBACCO INC,2011,JPO
JP2011231113A,CNRS,2011,JPO
JP2011239780A,NOVARTIS,2011,JPO
JP2011501661A,DU PONT,2011,JPO
JP2011504370A,DU PONT,2011,JPO
JP2011504734A,BASF,2011,JPO
JP2011505391A,SCHWEITZER CO LTD,2011,JPO
JP2011505865A,DU PONT,2011,JPO
JP2011507513A,NATIONAL RESEARCH COUNCIL CANADA,2011,JPO
JP2011508602A,CARGILL INC,2011,JPO
JP2011509085A,PROTERRO INC,2011,JPO
JP2011509655A,LUDWIG-MAXIMILIANS-UNIVERSITAT,2011,JPO
JP2011510611A,UNIVERSITY OF CALIFORNIA,2011,JPO
JP2011512151A,UKHSA,2011,JPO
JP2011512812A,GENESYS LTD GB,2011,JPO
JP2011512865A,COMPUGEN LTD. (IL),2011,JPO
JP2011512868A,DSM IP ASSETS BV,2011,JPO